Patents by Inventor Yongmei XIE

Yongmei XIE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240067672
    Abstract: Provided are a flavone derivative represented by formula I and a pharmaceutically acceptable salt, hydrate or solvate thereof. (I) In formula I, R1 is selected from the group consisting of H, C1-4 alkyl, amino and C1-4 acyl; R2 is isopentenyl or 2-hydroxy-isopentyl; R3 is selected from the group consisting of H, methyl and deuterated methyl; R4 is selected from the group consisting of C1-4 alkyl, amino, C1-4 acyl, and (II), wherein R5 represents a monosaccharide residue or an oligosaccharide residue; L is selected from the group consisting of a polypeptide, C1-C20 linear alkyl or a derivative thereof, a derivative of C1-C20 linear or branched acyl, C1-C20 glycol or a derivative thereof, and (III), wherein Y is (IV), a is an integer from 0-100, b is an integer from 1-100, c is an integer from 1-10, d is an integer from 0-100, and e is an integer from 0-100. The flavone derivative according to the present invention exhibits an potent and broad-spectrum anti-cancer activity.
    Type: Application
    Filed: June 8, 2020
    Publication date: February 29, 2024
    Inventors: Yongmei Xie, Xiangrong Song, Bo Luo
  • Publication number: 20230391732
    Abstract: The present disclosure provides a pyrazine compound, a stereoisomer, and a tautomer, and a pharmaceutically acceptable salt thereof in treating a neurodegenerative disease (ND) including Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal dementia (FTD), vascular dementia, HIV-related dementia, multiple sclerosis, progressive lateral sclerosis, Friedreich's ataxia, neuropathic pain, or glaucoma, diabetes mellitus (DM) and a DM-related complication, an inflammation, an oxidative damage, and a mitochondrial disorder-related disease.
    Type: Application
    Filed: July 30, 2021
    Publication date: December 7, 2023
    Applicant: SHENZHEN OLIVE BIOPHARMACEUTICALS CO., LTD
    Inventors: Yongmei XIE, Shupeng LI, Xifei YANG
  • Patent number: 11572382
    Abstract: The invention relates to novel camptothecin derivatives and their applications, tumor cell growth inhibitors, ternary complexes, and a method for improving the solubility of the camptothecin derivatives. The camptothecin derivatives are prepared by modifying the substance shown as Formula I with glycosylated triazole at position R3. In the structure shown as Formula I, R1 represents H, C1-10 alkyl, C1-10 alkyl-D or C1-10 haloalkyl; R2 represents H, CH2N(CH3)2 or CH2N(CD3)2; and R4 represents or H, wherein X represents N, O or S; and L represents polypeptide, C1-20 linear alkyl or derivatives thereof, C1-20 linear or branched acyl derivatives, C2-100 ethylene glycol or derivatives thereof. The camptothecin derivatives have high solubility, the anticancer drugs prepared from them have the advantages of wide anticancer spectrum and high safety, and have in vivo anticancer activity higher than irinotecan hydrochloride.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: February 7, 2023
    Assignee: TARGET BIOPHARMACEUTICAL TECHNOLOGY SHENZHEN COMPANY LIMITED
    Inventors: Yongmei Xie, Xiangrong Song, Xifei Yang, Yu Zhao, Bo Luo
  • Publication number: 20210246157
    Abstract: The invention relates to novel camptothecin derivatives and their applications, tumor cell growth inhibitors, ternary complexes, and a method for improving the solubility of the camptothecin derivatives. The camptothecin derivatives are prepared by modifying the substance shown as Formula I with glycosylated triazole at position R3. In the structure shown as Formula I, R1 represents H, C1-10 alkyl, C1-10 alkyl-D or C1-10 haloalkyl; R2 represents H, CH2N(CH3)2 or CH2N(CD3)2; and R4 represents or H, wherein X represents N, O or S; and L represents polypeptide. C1-20 linear alkyl or derivatives thereof. C1-20 linear or branched acyl derivatives, C2-100 ethylene glycol or derivatives thereof. The camptothecin derivatives have high solubility, the anticancer drugs prepared from them have the advantages of wide anticancer spectrum and high safety, and have in vivo anticancer activity higher than irinotecan hydrochloride.
    Type: Application
    Filed: August 15, 2019
    Publication date: August 12, 2021
    Inventors: Yongmei XIE, Xiangrong SONG, Xifei YANG, Yu ZHAO, Bo LUO
  • Patent number: 10346437
    Abstract: Described are techniques for processing event occurrence. A first notification may be received regarding a first occurrence of a first event. Responsive to receiving the first notification, first processing may be performed that includes mapping the first event to a first profile, and performing second processing using the first profile to collect first data regarding the first occurrence of the first event.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: July 9, 2019
    Assignee: EMC IP Holding Company LLC
    Inventors: Xin Zhong, Brian R. Tetreault, Wai Yim, Yongmei Xie
  • Patent number: 9507798
    Abstract: A technique for logging events in a data storage system involves designating one subset of storage processors of the data storage system as clients that generate log entries and another subset of the storage processors as servers that receive log entries. Only one server is active at a time. The active server receives the generated log entries from the clients and persists the log entries to a centralized log store. Clients assign first timestamps to the log entries based on locally accessible clocks. The active server receives the log entries, including the first timestamps, from the clients and applies second timestamps based on a clock accessible to the server. As the second timestamps are consistent across the different clients, the second timestamps can be applied to correct misalignments in time among the log entries received from the clients.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: November 29, 2016
    Assignee: EMC IP Holding Company LLC
    Inventors: Bingfeng Zhao, Jun Chen, Stephen M. Lathrop, Wai Chuen Yim, Yongmei Xie
  • Patent number: 9098566
    Abstract: Disclosed is an approach for presenting RDF data as a set of relational views. By presenting the RDF data as relational views, this permits integrated access to the RDF-based data from existing relational database tools, such as by asserting SQL queries against the relational views. One or more classes are identified within the RDF data, wherein a relational view of the set of the relational views maps properties relating to a particular class.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: August 4, 2015
    Assignee: ORACLE INTERNATIONAL CORPORATION
    Inventors: Jagannathan Srinivasan, Yongmei Xie, Jayanta Banerjee
  • Publication number: 20120303668
    Abstract: Disclosed is an approach for presenting RDF data as a set of relational views. By presenting the RDF data as relational views, this permits integrated access to the RDF-based data from relational tools.
    Type: Application
    Filed: May 24, 2011
    Publication date: November 29, 2012
    Applicant: ORACLE INTERNATIONAL CORPORATION
    Inventors: Jagannathan SRINIVASAN, Yongmei XIE, Jayanta BANERJEE